Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Real-world outcomes of teclistamab in triple-exposed relapsed/refractory multiple myeloma: Brazilian single-center experience

View Full Paper
Ask AI
Bookmark
Share

Authors

RHRicardo HelmanNHNelson Hamerschlak

Discussion

Loading...

Member takes

Overview

Retrospective analysis demonstrates 78% progression-free survival at 12 months in patients with relapsed multiple myeloma, suggesting teclistamab's potential in treatment.

Key Points

  • At 12 months, progression-free survival reached 78% for patients with relapsed/refractory multiple myeloma.
  • A median follow-up of 16 months revealed significant outcomes with teclistamab in hard-to-treat populations.
  • Retrospective analysis focused on triple-exposed patients who had undergone four prior therapy lines, enhancing findings.
  • Highlights the importance of real-world data for evaluating treatments like teclistamab for early-line therapy.

Cite This Study

Helman et al. (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dbf7https://doi.org/10.1182/blood-2025-7607
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world efficacy and safety of teclistamab in relapsed or refractory multiple myeloma: Results from 87 patients treated by the polish myeloma group2025
  2. 2Real-World Efficacy and Safety of Teclistamab for Patients with Relapsed or Refractory Multiple Myeloma: Nationwide Retrospective Analysis of the Named Patient Program in Korea2025 · 3 citations
  3. 3First results of the rwe prospective study TEC care (IFM 2023-01) evaluating teclistamab in triple-class exposed relapsed refractory multiple myeloma patients.2025
  4. 4Teclisito: Low-intensity teclistamab in the outpatient setting for Relapsed/Refractory multiple myeloma2025
  5. 5Real-world analysis of infection timing and burden in multiple myeloma patients treated with teclistamab2025